Longevity News

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

Source: PR Newswire • Published: 01 Jul 2026, 05:22

MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe

European update on a company's coordinated clinical and market push to expand tech-enabled stroke rehabilitation across care settings.

Key Takeaways
  • SwissNeuroRehab has enrolled first patients in a multicenter HDHI neurorehabilitation study
  • Study targets 300 minutes of active training per week across inpatient and home phases
  • MindMaze's parallel REACT-AVC study will generate clinical and health-economic evidence for reimbursement
Read Original Source